Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for NextCell Pharma AB's Gross Margin % or its related term are showing as below:
FRA:65G'
s Gross Margin % Range Over the Past 10 Years
Min: -1779.3 Med: -173.52 Max: 14.08
Current: 10.72
During the past 11 years, the highestGross Margin % of NextCell Pharma AB was 14.08%. The lowest was -1779.30%. And the median was -173.52%.
FRA:65G's Gross Margin % is ranked worse than 89.89% of 732
companies
in the Biotechnology industry
Industry Median: 60.915
vs FRA:65G: 10.72
NextCell Pharma AB had a gross margin of -9.20% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for NextCell Pharma AB was 0.00% per year.
NextCell Pharma AB (FRA:65G) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
NextCell Pharma AB had a gross margin of -9.20% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
NextCell Pharma AB Gross Margin % Related Terms
NextCell Pharma AB Gross Margin % Historical Data
* Premium members only.
The historical data trend for NextCell Pharma AB's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:65G vs VRTX, REGN, RVMD: Gross Margin % Comparison
For the Biotechnology subindustry, NextCell Pharma AB's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NextCell Pharma AB Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NextCell Pharma AB's Gross Margin % distribution charts can be found below:
* The bar in red indicates where NextCell Pharma AB's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
NextCell Pharma AB (FRA:65G) has a Gross Margin % of -9.20% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on NextCell Pharma AB and its competitors. According to the industry distribution chart, NextCell Pharma AB ranks #658 out of 732 companies in the Biotechnology industry, placing it in the top 89.9%.
Is NextCell Pharma AB's Gross Margin % too high?
NextCell Pharma AB's current Gross Margin % is -9.20%. Based on the distribution chart, NextCell Pharma AB ranks #658 out of 732 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NextCell Pharma AB has a GF Score™ of 42/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NextCell Pharma AB's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, NextCell Pharma AB ranks #658 out of 732 companies for Gross Margin %. This places NextCell Pharma AB in the lower half of its industry. The industry median Gross Margin % is 60.92. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on NextCell Pharma AB and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NextCell Pharma AB's current Gross Margin % is -9.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NextCell Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, NextCell Pharma AB (FRA:65G) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.06, compared to a current price of €0.07 — trading 21% above its estimated fair value. The current Gross Margin % is -9.20%. NextCell Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For NextCell Pharma AB (FRA:65G), the current Gross Margin % is -9.20% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NextCell Pharma AB (FRA:65G) Overvalued in 2026?
Based on GuruFocus' analysis, NextCell Pharma AB stock appears to be overvalued.
The current stock price of €0.07 is trading 21% above its estimated GF Value™ of €0.06.
GuruFocus considers NextCell Pharma AB to be Modestly Overvalued.
Key valuation signals for FRA:65G:
Gross Margin %: -9.20%
GF Value™: €0.06 vs. price of €0.07 (21% above fair value)
No single metric tells the full story. See the FRA:65G stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.
42GF Score
Get the complete analysis for FRA:65G
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:65G has been successfully added to your 
